Day One Biopharmaceuticals Inc
DAWN9.600USD
-0.030-0.31%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
985.68MMarket Cap
LossP/E TTM
More Details of Day One Biopharmaceuticals Inc Company
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.
Day One Biopharmaceuticals Inc Info
Ticker SymbolDAWN
Company nameDay One Biopharmaceuticals Inc
IPO dateMay 27, 2021
CEOBender (Jeremy)
Number of employees181
Security typeOrdinary Share
Fiscal year-endMay 27
Address1800 Sierra Point Parkway, Suite 200
CityBRISBANE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94005
Phone16504840899
Websitehttps://dayonebio.com/
Ticker SymbolDAWN
IPO dateMay 27, 2021
CEOBender (Jeremy)
Company Executives of Day One Biopharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.82M
+0.88%
Mr. Adam Dubow
Mr. Adam Dubow
General Counsel, Chief Compliance Officer and Secretary
General Counsel, Chief Compliance Officer and Secretary
74.71K
+11.60%
Ms. Lauren Merendino
Ms. Lauren Merendino
Chief Commercial Officer
Chief Commercial Officer
48.74K
+16.24%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
40.48K
--
Mr. Scott Garland
Mr. Scott Garland
Independent Director
Independent Director
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Natalie C. Holles
Ms. Natalie C. Holles
Independent Director
Independent Director
--
--
Dr. John A. Josey, Ph.D.
Dr. John A. Josey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles N. York, II
Mr. Charles N. York, II
Chief Financial Officer, Chief Operating Officer, Secretary
Chief Financial Officer, Chief Operating Officer, Secretary
--
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.82M
+0.88%
Mr. Adam Dubow
Mr. Adam Dubow
General Counsel, Chief Compliance Officer and Secretary
General Counsel, Chief Compliance Officer and Secretary
74.71K
+11.60%
Ms. Lauren Merendino
Ms. Lauren Merendino
Chief Commercial Officer
Chief Commercial Officer
48.74K
+16.24%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
40.48K
--
Mr. Scott Garland
Mr. Scott Garland
Independent Director
Independent Director
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
33.91M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Access Industries, Inc.
12.59%
Fidelity Management & Research Company LLC
7.41%
Atlas Venture
6.26%
BlackRock Institutional Trust Company, N.A.
6.26%
The Vanguard Group, Inc.
6.01%
Other
61.47%
Shareholders
Shareholders
Proportion
Access Industries, Inc.
12.59%
Fidelity Management & Research Company LLC
7.41%
Atlas Venture
6.26%
BlackRock Institutional Trust Company, N.A.
6.26%
The Vanguard Group, Inc.
6.01%
Other
61.47%
Shareholder Types
Shareholders
Proportion
Investment Advisor
28.21%
Hedge Fund
23.75%
Investment Advisor/Hedge Fund
20.33%
Corporation
12.59%
Venture Capital
6.34%
Individual Investor
4.35%
Research Firm
4.03%
Private Equity
1.39%
Bank and Trust
0.23%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
390
86.52M
115.65%
+81.15K
2025Q3
401
86.44M
119.83%
-942.76K
2025Q2
390
87.37M
118.27%
-8.42M
2025Q1
389
95.92M
111.30%
-16.89M
2024Q4
373
95.70M
104.59%
+1.59M
2024Q3
359
93.92M
88.75%
+17.37M
2024Q2
339
76.41M
96.74%
+2.06M
2024Q1
320
74.24M
101.26%
-14.24M
2023Q4
310
78.10M
98.05%
-1.14M
2023Q3
293
79.06M
97.82%
-960.32K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Access Industries, Inc.
12.93M
12.62%
--
--
Aug 01, 2024
Fidelity Management & Research Company LLC
9.20M
8.98%
-2.18M
-19.19%
Jun 30, 2025
Atlas Venture
6.43M
6.28%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.80M
6.64%
+1.62M
+31.20%
Jun 30, 2025
The Vanguard Group, Inc.
6.16M
6.02%
+233.25K
+3.93%
Jun 30, 2025
Deerfield Management Company, L.P.
3.72M
3.63%
+762.39K
+25.75%
Jun 30, 2025
Franklin Advisers, Inc.
4.05M
3.95%
+74.15K
+1.86%
Jun 30, 2025
State Street Investment Management (US)
2.69M
2.63%
-17.01K
-0.63%
Jun 30, 2025
Vestal Point Capital, LP
3.00M
2.93%
+401.87K
+15.47%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Products ETF
1.78%
ALPS Medical Breakthroughs ETF
0.32%
State Street SPDR S&P Biotech ETF
0.23%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
WisdomTree US SmallCap Fund
0.12%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.08%
Fidelity Fundamental Small-Mid Cap ETF
0.07%
iShares Biotechnology ETF
0.05%
Pacer WealthShield ETF
0.04%
View more
Virtus LifeSci Biotech Products ETF
Proportion1.78%
ALPS Medical Breakthroughs ETF
Proportion0.32%
State Street SPDR S&P Biotech ETF
Proportion0.23%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.14%
WisdomTree US SmallCap Fund
Proportion0.12%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.07%
iShares Biotechnology ETF
Proportion0.05%
Pacer WealthShield ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Day One Biopharmaceuticals Inc?
The top five shareholders of Day One Biopharmaceuticals Inc are:
Access Industries, Inc. holds 12.93M shares, accounting for 12.62% of the total shares.
Fidelity Management & Research Company LLC holds 9.20M shares, accounting for 8.98% of the total shares.
Atlas Venture holds 6.43M shares, accounting for 6.28% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.80M shares, accounting for 6.64% of the total shares.
The Vanguard Group, Inc. holds 6.16M shares, accounting for 6.02% of the total shares.
Access Industries, Inc. holds 12.93M shares, accounting for 12.62% of the total shares.
Fidelity Management & Research Company LLC holds 9.20M shares, accounting for 8.98% of the total shares.
Atlas Venture holds 6.43M shares, accounting for 6.28% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.80M shares, accounting for 6.64% of the total shares.
The Vanguard Group, Inc. holds 6.16M shares, accounting for 6.02% of the total shares.
What are the top three shareholder types of Day One Biopharmaceuticals Inc?
The top three shareholder types of Day One Biopharmaceuticals Inc are:
Access Industries, Inc.
Fidelity Management & Research Company LLC
Atlas Venture
Access Industries, Inc.
Fidelity Management & Research Company LLC
Atlas Venture
How many institutions hold shares of Day One Biopharmaceuticals Inc (DAWN)?
As of 2025Q4, 390 institutions hold shares of Day One Biopharmaceuticals Inc, with a combined market value of approximately 86.52M, accounting for 115.65% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.18%.
What is the biggest source of revenue for Day One Biopharmaceuticals Inc?
In FY2025Q2, the -- business generated the highest revenue for Day One Biopharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
